Trial · NCT01857310
Outcomes38
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 38 of 38
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Major Neonatal Complications | Delivery | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Structural Malformations | Delivery | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Severe Maternal Morbidity | Delivery | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Fertilization Rate Per Cycle, % | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Fertilization rate unavailable in medical records for 17 and 28 participants in the active and placebo arms, respectively | percent per cycle | MEAN |
| SECONDARY | Number of Good Quality Embryos on Day 5 Per Cycle | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Day 5 good quality embryos unavailable in medical records for 56 and 64 participants in the active and placebo arms, respectively | embryos per cycle | MEAN |
| SECONDARY | Percentage of Good Quality Embryos on Day 5 Per Cycle | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Proportion day 5 good quality embryos unavailable in medical records for 17 and 28 participants in the active and placebo arms, respectively | percent per cycle | MEAN |
| SECONDARY | Number of Embryos Transferred Per Cycle | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Proportion day 5 good quality embryos unavailable in medical records for 7 and 9 participants in the active and placebo arms, respectively | embryos per cycle | MEAN |
| SECONDARY | Number of Embryos Cryopreserved Per Cycle | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Number of embryos cryopreserved unavailable in medical records for 40 and 35 participants in the active and placebo arms, respectively | embryos per cycle | MEAN |
| SECONDARY | Sperm Penetration Per Cycle, % | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Sperm penetration \& unavailable in medical records for 114 and 121 participants in the active and placebo arms, respectively | percent penetration | MEAN |
| SECONDARY | Cells on Day 3 Per Embryo Per Cycle | Up to 9 months of fertility treatment post-randomization | 1215 embryos among cycles among women in the FA/Zn arm; 1129 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively~\# of cells on day 3 unavailable in medical records for 25 and 36 participants in the active and placebo arms, respectively | cells per embryo | MEAN |
| SECONDARY | Cells on Day 3 Per Embryo Per Cycle, Categorical | Up to 9 months of fertility treatment post-randomization | 1222 embryos among cycles among women in the FA/Zn arm; 1140 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively~\# of cells on day 3 (categorical) unavailable in medical records for 25 and 36 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| SECONDARY | Cells on Day 5 Per Embryo Per Cycle, Categorical | Up to 9 months of fertility treatment post-randomization | 1160 embryos among cycles among women in the FA/Zn arm and 1205 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively~\# of cells on day 5 (categorical) unavailable in medical records for 5 and 14 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| SECONDARY | Embryo Morphology on Day 3 Per Cycle, Categorical | Up to 9 months of fertility treatment post-randomization | 961 embryos among cycles among women in the FA/Zn arm; 931 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Embryo morphology on day 3 (categorical) unavailable in medical records for 27 and 37 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| SECONDARY | Embryo Morphology on Day 5 Per Cycle, Categorical | Up to 9 months of fertility treatment post-randomization | 973 embryos among cycles among women in the FA/Zn arm; 1009 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Embryo morphology on day 5 (categorical) unavailable in medical records for 10 and 19 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| SECONDARY | Method of Fertilization Per Cycle | Up to 9 months of fertility treatment post-randomization | 1689 embryos among cycles among women in the active treatment arm; 1800 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Method of fertilization unavailable in medical records for 2 and 5 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| SECONDARY | Quality of Embryos Transferred Per Cycle, Categorical | Up to 9 months of fertility treatment post-randomization | 172 embryos among cycles among women in the FA/Zn arm; 187 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Quality of embryos transferred (categorical) unavailable in medical records for 21 and 30 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| SECONDARY | Chromosomal Complement of Embryo Per Cycle | Up to 9 months of fertility treatment post-randomization | 124 and 135 participants randomized to active and placebo arms, respectively Chromosomal complement of embryo unavailable in medical records for 121 and 124 participants in the active and placebo arms, respectively | predicted probability | NUMBER |
| OTHER_PRE_SPECIFIED | Reproductive Hormones and Other Measured Biomarkers | 4 or 6 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01857310/outcomes?page=2